Overview

A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)

Status:
Completed

Trial end date:
2019-06-21

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if ABI-H0731 given in combination with a standard of care (SOC) entecavir (ETV) is safe and effective in participants with chronic hepatitis B infection (cHBV)

Phase:

Phase 2

Details

Lead Sponsor:

Assembly Biosciences

Treatments:

Entecavir